Association between insulin resistance and abnormal menstrual cycle in Chinese patients with polycystic ovary syndrome

Abstract

Background Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder, which is characterized by insulin resistance (IR) and menstrual cycle disorders. IR is thought of as a pivotal cause of PCOS and related comorbidities. However, the link between IR and abnormal menstrual cycles in PCOS should be further studied. In this study, we clarified the dose–response relationship between IR and abnormal menstrual cycles in patients with PCOS. Results In this retrospective study including 140 patients with PCOS, we found that there was a dose–response relationship between the increased HOMA-IR index and the level of menstrual cycle disorders (1.61 [95%CI: 1.37–1.85] for normal menstruation, 2.02 [95%CI: 1.61–2.44] for oligomenorrhea, 2.35 [95%CI:1.96–2.75] for amenorrhea, P for trend = 0.003). Further stratification analyses showed that this dose–response relationship was more evident in the patients who were younger, had higher BMI, higher AFC numbers, elevated levels of testosterone, anti-Müllerian hormone, inhibin B, and prolactin levels, and had a lower progestogen level. Conclusions Our study has established an association between IR and abnormal menstrual cycles in patients with PCOS, which can be affected by age, BMI, and hormone levels. Our results might be helpful for further prevention and treatment of amenorrhea in PCOS.

Total weight loss rather than preoperative body mass index correlates with remission of irregular menstruation after sleeve gastrectomy in patients with polycystic ovary syndrome

“…Obesity is the most common cause of insulin resistance and compensatory hyperinsulinemia, which are the primary pathological features of PCOS. Previous studies have demonstrated that insulin resistance plays a role in determining the degree of menstrual irregularity in patients with PCOS ( 22 , 23 ). However, in the current study, for PCOS patients with an average BMI of 40.91 kg/m 2 , no significant differences were observed in HOMA-IR and AUC insulin of OGTT values among the different BMI groups; therefore, it is reasonable for these patients to have a similar response to SG in the remission of irregular menstruation.…”

Harnessing Technology to Revolutionize Personalized Therapies for Metrorrhagia

“…Uterine structural abnormalities like fibroids, polyps, and hyperplasia often underly metrorrhagia in premenopausal women. Endometrial cancer, though rare before menopause, has a peak incidence at 55-64 years old and should be ruled out in postmenopausal bleeding [8][9][10][11].…”